Download the Case Study
Navigating the Challenges of Complex First-in-Human Studies
Navigating the Challenges of Complex First-in-Human Studies
Advancing the Translational Development of a Novel Biologic into a First-in-Human Clinical Trial for a Rare Disease
Developing novel biologics for rare diseases can involve complex First-in-Human (FIH) study designs, requiring careful dose escalation, participant recruitment, and specialized assessments to evaluate safety and pharmacology activity. These early- phase trials often require extensive operational coordination to maintain study timelines, data quality, and participant engagement.
The following case study highlights how Medpace leveraged integrated Phase I capabilities and operational expertise to successfully execute a FIH rare disease study.
Your Next Breakthrough Starts Here
The medpace Phase i unit
Medpace’s Phase I Unit is purpose-built to support first-in-human through proof-of-concept studies with integrated clinical, scientific, and operational expertise. As part of Medpace’s full-service CRO model, the unit combines specialized healthy volunteer recruitment, an integrated research campus, and dedicated early-phase capabilities to help Sponsors efficiently execute complex study designs. With seamless collaboration across functional teams and a flexible, solutions-oriented approach, Medpace helps Sponsors advance innovative therapies while maintaining study quality and operational efficiency. By connecting early-phase research with Medpace’s broader clinical development expertise, the Phase I Unit provides Sponsors with a seamless pathway from initial study design through late-stage development.
